The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Homeowners frequently misjudge the value of their homes, often by tens of thousands of dollars and these belief-driven errors significantly alter how much they invest, save, and consume. The study ...

The mean of analysts' price targets for Omnicom (OMC) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

An annual hearing to review the threats facing the U.S. ended with an effort by Democrats to subpoena Homeland Security ...

Shares of Evolv Technologies Holdings, Inc. (EVLV) have gained 0.7% over the past four weeks to close the last trading session at $6.77, but there could still be a solid upside left in the stock if ...

Helen Mirren's willingness to wear a bold dress for her red carpet appearance is a celebrated act of defiance against ageism ...

SPGP's Energy sector exposure was dramatically reduced at its last semi-annual reconstitution, and this change was positive ...

Tenaya Therapeutics (TNYA) announced interim data from the ongoing RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for the potential ...

TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week ...

Building a bond ladder. Expanding offense and defense with select ETFs—including QQQ, RSP, GOVI, TBF, and UVIX—enables tactical flexibility amid high market correlation. Listen here or on the go via ...

Objective To quantify the time lag between biomedical articles and the studies they describe as “recent,” a term widely used to imply timeliness despite rarely reflecting the actual age of the cited ...